Brand drug nam­ing faces chal­lenges in emerg­ing cat­e­gories, ex­pert says

As brand drug nam­ing gets more dif­fi­cult, some ther­a­py ar­eas like obe­si­ty and Alzheimer’s dis­ease are fac­ing even more chal­lenges. That’s be­cause both are tra­di­tion­al­ly more con­ser­v­a­tive cat­e­gories when it comes to the kinds of names the FDA will al­low.

Hint­ing at ben­e­fits, or even sub­tle im­pli­ca­tions, such as weight loss or mem­o­ry gain, are par­tic­u­lar­ly frowned up­on, said Brand In­sti­tute’s pres­i­dent of cre­ative, Scott Pier­grossi.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER